A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.
Richard L. Kravitz, MD, MSPH and Jodi Halpern, MD, PhD
Patients have a responsibility to discerningly present the drug information they receive from direct-to-consumer advertising and to be active partners with their physician in making health care decisions.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Physicians and surrogates should take patients' preferences into account in making clinical intervention decisions, even if the patients have been found to lack decision-making capacity.
Physicians and surrogates should take patients' preferences into account in making clinical intervention decisions, even if the patients have been found to lack decision-making capacity.
Physicians and surrogates should take patients' preferences into account in making clinical intervention decisions, even if the patients have been found to lack decision-making capacity.
A landmark court case in California determined that a competent adult patient has the right to forgo medical treatment and the patient's autonomy supersedes the state's interest in preserving the patient's life.
Several recent court cases illustrate how some states are attempting to mandate physician reporting of all underage sexual activity as instances of child abuse.